[EN] HEPATITIS B CAPSID ASSEMBLY MODULATORS<br/>[FR] MODULATEURS D'ASSEMBLAGE DE CAPSIDE DE L'HÉPATITE B
申请人:VENATORX PHARMACEUTICALS INC
公开号:WO2021119081A1
公开(公告)日:2021-06-17
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
[EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
申请人:CELGENE AVILOMICS RES INC
公开号:WO2014144737A1
公开(公告)日:2014-09-18
The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
[EN] BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLYL-MÉTHYLURÉE EN TANT QU'AGONISTES DU RÉCEPTEUR ALX
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2015019325A1
公开(公告)日:2015-02-12
The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
[EN] AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS<br/>[FR] DÉRIVÉS DE L'AMINOPYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS SÉLECTIFS D'ALK-2
申请人:NOVARTIS AG
公开号:WO2018014829A1
公开(公告)日:2018-01-25
The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
[EN] IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDMIN-2-YL COMME INHIBITEURS DE LA JAK
申请人:ALMIRALL SA
公开号:WO2015091531A1
公开(公告)日:2015-06-25
New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.